Q-omics provides the consensus-scored ZBTB12 profile across patient tissues and cancer cell-line models. ZBTB12 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZBTB12 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ZBTB12 RNA expression shows 20,649 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where ZBTB12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB12 survival associations across molecular data types. ZBTB12 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB12 RNA expression–survival associations across cancer types. High ZBTB12 expression shows unfavorable associations in ACC, COAD and LIHC, but favorable associations in UVM, BLCA and UCS. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZBTB12 RNA expression.
This table summarizes ZBTB12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB12 shows higher tumor expression in COAD, LIHC, KIRP, LUAD, KIRC and STAD. The COAD box plot shows higher ZBTB12 RNA expression in tumor versus normal tissue (log2 FC = +1.870, t-test p < 0.001).
This table shows molecular features associated with ZBTB12 in patient tissues and cancer cell lines. In patient samples, ZBTB12 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
